



Vesalius ∞

LONGEVITY LABS

Investor Presentation – September 2026

CSE: VLAB

HEALTH BEYOND OUTCOMES · LIFE BEYOND BASELINE

BUILDING THE LEADING GLOBAL PEPTIDE AND LONGEVITY BRAND

Forward Looking Statements.



This presentation (the “Presentation”) of Vesalius Longevity Labs (Canada) Inc. (the “Company”) is dated March 5, 2026. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation, or needs of any particular investor. The contents of this Presentation are not to be construed as legal, financial, or tax advice.

Certain statements contained in this Presentation constitute forward-looking statements and forward-looking information (collectively, “forward-looking statements”). Such forward-looking statements relate to possible events, conditions or financial performance of the Company based on future economic conditions and courses of action. All statements other than statements of historical fact are forward-looking statements. The use of any words or phrases such as “seek,” “anticipate,” “plan,” “continue,” “estimate,” “expect,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “believes,” “estimated,” “intends,” “plans,” “projection,” “outlook” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements include, among others, the Company’s (i) ability to implement its growth strategy, including, but not limited to, its ability to attract and retain experienced management personnel, expand into additional geographical regions, enhance its product offering, and to capitalize on growth opportunities; (ii) financial outlook (iii) ability to complete the business combination transaction with Sweet Earth Holdings Corporation on the terms announced or at all (iv) the perceived benefits from the Company’s royalty agreement with MuseCell (v) the timing and payment of the Company’s payment obligations under its agreement with MuseCell. These statements involve known and unknown risks, assumptions, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements.

The forward-looking statements are based on management’s current opinions, estimates and assumptions in light of our experience and perception of historical trends, current trends, current conditions and expected future developments, as well as other factors that management currently believes appropriate and reasonable in the circumstances, including, among others, (a) the Company will continue to effectively execute against its key strategic growth priorities, without any material adverse impact from macroeconomic or geopolitical headwinds on its or its customers’ business, financial condition, financial performance, liquidity or any significant reduction in demand for its products and services, (b) the economic conditions in the Company’s core markets, geographies and verticals remaining at close to current levels, (c) assumptions as to interest rates and inflation, (d) the Company’s continued ability to manage its growth effectively, (e) the Company’s ability to continue to attract and retain key talent and personnel required to achieve its plans and strategies, including sales, marketing, support and product and technology operations, in each case both domestically and internationally, (f) the Company’s ability to successfully identify, complete, integrate and realize the expected benefits of acquisitions and manage the associated risks, as well as future acquisitions, (g) the absence of adverse changes in legislative or regulatory matters, including in the regulation of peptide supplements in the United States and other jurisdictions, (h) the Company’s continued ability to upskill and modify its compliance capabilities as regulations change or as the Company enters new markets or offers new products or services, (i) the Company’s continued ability to access liquidity and capital resources, including its ability to secure debt or equity financing on satisfactory terms, and (j) the absence of adverse changes in current tax laws, (k) the continued availability and stability of the Company’s supply chain for peptide and bioregulator products, including the absence of material disruptions to the sourcing, manufacturing, or importation of such products from domestic or international suppliers, (l) the Company’s ability to maintain product quality, purity, and consistency standards for its peptide and bioregulator products in accordance with applicable regulatory and industry requirements, and the absence of any material product recalls, safety alerts, or adverse event reports that could negatively impact consumer confidence or regulatory standing, (m) the absence of any reclassification of the Company’s peptide or bioregulator products by applicable regulatory authorities, including the United States Food and Drug Administration (FDA) or equivalent regulatory bodies in other jurisdictions, from their current regulatory classification to a more restrictive classification, such as prescription drugs or controlled substances, (n) the Company’s ability to obtain and maintain all necessary licenses, permits, and approvals required for the lawful distribution and sale of peptide and bioregulator products in each jurisdiction in which it operates or intends to operate, (o) the absence of material adverse developments in the scientific or medical literature regarding the safety or efficacy of peptide or bioregulator products that could negatively affect consumer demand or regulatory treatment of such products, (p) the Company’s ability to protect its proprietary formulations, trade secrets, and intellectual property rights in connection with its peptide and bioregulator products, and the absence of material intellectual property disputes or infringement claims, (q) the continued and growing consumer awareness of and demand for peptide and bioregulator products for health, wellness, and longevity purposes, and the absence of material adverse shifts in consumer sentiment or market trends, (r) the Company’s ability to successfully navigate customs, import/export controls, and cross-border regulatory requirements applicable to

the international distribution of peptide and bioregulator products, (s) the absence of material adverse actions by payment processors, financial institutions, or e-commerce platforms that could restrict or limit the Company’s ability to process transactions or distribute its products through digital or online channels, and (t) the Company’s ability to maintain and grow its distribution network, including relationships with key distributors, retailers, and e-commerce partners, without material disruption. The Company believes there is a reasonable basis for the expectations reflected in the forward-looking statements; however, no assurance can be given that these expectations and the underlying opinions, estimates, and assumptions will prove to be correct. The forward-looking statements included in this Presentation should not be unduly relied upon by investors.

All of the forward-looking statements and information contained in this Presentation speak only as of the date of this Presentation and are expressly qualified by the foregoing cautionary statements. The Company expressly disclaims any obligation to update or alter statements containing any forward-looking statements, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by applicable law.

This Presentation includes market and industry data obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this Presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information. Some numbers in this Presentation may not be exact or add consistently due to rounding.

By your acceptance of this Presentation, you agree that the information in this Presentation constitutes confidential proprietary information of the Company. You and any person reviewing this Presentation agrees not to distribute, copy, reproduce, transmit, make available, or condone any of the foregoing, without the prior written consent of the Company. Any unauthorized use of this Presentation is strictly prohibited.

This Presentation may have been sent to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. As a consequence of the above, neither the Company nor any director, officer, employee or agent of any of them or any affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the document distributed to you in electronic format and the hard copy version that may be made available to you.

Investment highlights.



Building the leading global, peptide and longevity brand.

- **Massive and Expanding Market**

Global Wellness Economy estimated at **US\$6.3 trillion** with projected growth of **7.3% annually** over the next five years. Global peptide therapeutics market projected to grow from approximately **US\$43 billion to US\$106 billion by 2033**.

- **First-Mover Public Market Opportunity**

One of the first publicly traded companies focused exclusively longevity science.

- **Scalable Revenue Model with Multiple Growth Engines**

B2Doctor2Consumer distribution platform serving licensed healthcare providers. Royal Longevity subsidiary holds a revenue and royalty-generating agreement tied to MuseCell Innovations' licensed U.S. labs.

- **Global Platform**

Doctor distribution network across North America, Europe, UAE, Asia Pacific, and Latin America.

- **Defined Expansion Strategy:**

Active expansion into global markets with provider onboarding and strategic partnerships underway.

- **Recurring Healthcare and Wellness Revenue Streams**

Peptual portfolio, Telemedicine, MCI collaboration (Peptual Skin x DEZAWA MUSECELLS®).

- **Strong Leadership & Advisory Team**

Board, scientific advisors, and management bring expertise across healthcare, biotech, fintech, consumer platforms, and public markets.

Vesalius at a glance.



Building the leading global peptide and longevity brand.

\$8.9M

TOTAL 12 MONTH
REVENUE

Jul '25 - July '26

48%

BLENDED GROSS MARGIN

Across all verticals

+66%


REVENUE GROWTH

(Q4 '25: \$1.37M vs Q1 '26: \$2.28M)

~350

ACTIVE PROVIDERS

120 new YTD



3 REVENUE STREAMS

Peptual portfolio, Pens, Telemedicine, and MCI (MuseCell) collaboration driving recurring revenue.

4 KEY MARKETS

North America, Latin America, UAE, UK/EU.

~50M SOCIAL REACH

Strategic advisors combined social reach of 50M. Active expansion underway globally.

The global wellness economy. Why now?



As molecular signaling becomes central to preventative medicine, peptides are emerging as one of the fastest-growing therapeutic classes.

TAM: US\$6.3 TRILLION

THE PROBLEM

Multi-System Biological Decline

- Most adults face metabolic & hormonal decline.
- Massive demand for tools that restore core pathways.
- 88% of Americans 40+ show metabolic dysfunction.

THE OPPORTUNITY

A Trillion-Dollar Market

- Global Wellness Economy: US\$6.3 trillion.
- Peptide therapeutics: US\$43B today → US\$106B by 2033.
- Adoption accelerating across leading clinicians.

What are peptides?



Short chains of amino acids that act as targeted biological signals — activating the body's natural ability to repair, regulate, and optimize.



Cognitive

Mental Clarity

Neuroplasticity support

Mental clarity, focus, and neuroplasticity.



Performance

Strength

Physical output

Strength, stamina, recovery, and physical output.



Immune & Metabolic

Resilience

Weight & glucose

Immune resilience, inflammation reduction, metabolic efficiency.



Hormone & Longevity

Anti-Aging

Hormonal support

Healthy testosterone, estrogen, growth hormone regulation, and anti-aging pathways.

WHY PEPTIDES MATTER / BACKED BY CLINICAL SCIENCE

DEFINITION

- Bridging traditional medicine and the optimization era.
- Led by world-renowned MDs and biotech veterans with deep formulation expertise.
- Backed by clinical science and highly adaptable, peptides are unlocking the next frontier in proactive healthcare—bridging traditional medicine and the optimization era.

DELIVERY FORMATS

- Injectable Pens - precise, high-bioavailability dosing
- Nasal Sprays - fast-acting mucosal delivery
- Transdermal Patches - sustained-release topical formulations

Global peptide therapeutics market opportunity.



The peptide therapeutics market is nearly doubling in under a decade. Vesalius is positioned at the intersection of longevity science and peptide innovation — a rapidly commercializing space with regulatory tailwinds and institutional momentum.

TOTAL ADDRESSABLE MARKET

\$295B

BY 2033

Projected market value by 2033 (Grand View Research, 2025), up from \$141B in 2025. Fueled by GLP-1 adoption, AI-driven peptide discovery, and expanding indications in oncology, metabolic disorders, and longevity medicine.

MARKET SEGMENTS		
Metabolic Disorders & GLP-1	\$88B+	6.31% CAGR
Oncology & Cancer Peptides	\$43B+	8.7% CAGR
Longevity & Regenerative Medicine	\$28B+	12.3% CAGR
Peptide Synthesis & Manufacturing	\$2.3B+	12.7% CAGR

GLOBAL CAGR

8.73%

North America leads (45-62% share); Asia Pacific fastest-growing (6.2% CAGR); Europe a key established market; Latin America emerging. Vesalius targets North America and key regulatory-friendly markets globally.

REGIONS

4

Vesalius product portfolio.



Four key revenue streams.



Peptual (Peptides)

\$4.40M Jul 25- Apr 26
60% of total revenue

*Dominant channel. Scaling MoM.
Q1 '26: \$2.21M.
~60% of business*



Pens

\$1.64M Jul 25- Apr 26
Strong recurring revenue


*Multi-location operators. Apr '26:
\$341K. Large distributor scaling to
\$1M/mo.*



Telehealth

\$1.25M Jul 25- Apr 26
RZ pharmacy Q2 '26

*RZ Pharmacy launch Q2 '26 for re-
acceleration.
Average \$139K/mo.
Re-engaging top performing
influencers*



Dezawa MUSE® Exosomes®

Yr 1: Total Revenue
Forecast \$17.6M Yr 5

*MCI regenerative line. 5%
commission house / 20% field.
Peptual x Dezawa Aesthetics launch*

B2DOCTOR2CONSUMER CHANNEL

~350 providers on platform | 4 global markets

B2CONSUMER CHANNEL

Funnel through online & Influencer engagement

ROYALTY AGREEMENT

High margin | 5% distribution agreement

Dezawa Musecell[®] royalty partnership.

Through its 100% controlled subsidiary, Royal Longevity DBA (RegenProcessing.com), holds a distribution-as-a-service contract entitling Vesalius to earn royalties from a MCI licensed USA lab. This is part of an expansion program to include other existing mature MCI markets. This positioning is a gateway to a multiple additional biologics and commercial opportunities.


This strategic access point, revenue and EBITDA contribution of this agreement is forecasted to be significant to Vesalius and further solidify its position as the best-in-class platform for leading quality longevity products, therapies and genetic material.

5% royalty agreement

Dezawa MuseCell[®] advantage.

Backed by more than 120 publications including Phase II clinical trials conducted in Japan genuine Dezawa MuseCells[®] are supported by one of the most substantial dedicated evidence bases of any emerging stem cell population.

Manufactured in the US, Only Dezawa MuseCells[®] manufactured under strict licensed process are supported by these claims.




**DISCOVERED IN 2010 BY
PROFESSOR MARI DEZAWA, PHD**

Naturally occurring, UC-derived,
pluripotent-like stem cells
produced under patented
methodologies and documented
standards.

Revenue by channel.



Jul 2025 to July 2026. \$8.9M total. 9x run-rate growth.



CHANNEL PERFORMANCE / TRAILING 10 MONTHS

60%

Peptual (Peptides) core business

23%

Pens steady contributor

17%

Telehealth opportunity

Execution roadmap. Where we are going



NOW + NEXT in commercial execution. 5-year base case CY2026–CY2030. Calendar Year basis.

NOW

Optimize & Retain

- B2Doctor2Consumer - top-tier provider buying \$40K/mo. Scale Potential. ~350 providers on platform
- Launched commercial sales force: 3 field reps + 2 insidereps deploying
- Peptual lyophilized + injectable pens (core SKUs).
- Expanding distribution network and global footprint
- 2026 — marketing focus to accelerate provider acquisition and deepen clinic retention.

NEXT


Scale Verticals, Global Commercialization

- Royal Longevity distribution
- Peptual RZ pharmacy projected to launch Q3
- Future distribution markets: South America, Australia, Japan, Middle East
- Global expansion: scale to 20 US reps Yr 2+.
- Potential large partnerships in pipeline

How we win. Where we are going.



NOW + NEXT in commercial execution. 5-year base case Nov 2025 to Oct 2030. Year End October 31



Q1/Q2 Actuals (Nov '25–Apr '26). Q3–Q4 Forecast.

Yr 1	
(Nov '25 – Oct '26)	\$18.5M
Yr 2	
(Nov '26 – Oct '27)	\$54.2M
Yr 3	
(Nov '27 – Oct '28)	\$90.9M
Yr 4	
(Nov '28 – Oct '29)	\$132.3M
Yr 5	
(Nov '29 – Oct '30)	\$161.0M

Source: Vesalius Forecast V3 (Nov '25 – Oct '30). FY2026 Q1/Q2 actuals + forecast. Includes Sales (Direct), Pens, MuseCell Skincare, Peptual RZ Pharmacy, Distribution (Royal Longevity), and Peptual Beverage.



Global distribution & BD.

4 active markets. 4 US distribution groups. Targeting Australia, Japan and unlocking LatAm.

United States

ACTIVE

4 active distribution groups. Direct clinic sales. Core market.

BUSINESS DEVELOPMENT

BD: Peptual RZ pharmacy launch (Q2 '26). Expand distributor coverage.

UK / European Union

ACTIVE

Established distribution. Royal Longevity EU + 2 local longevity chains.

BUSINESS DEVELOPMENT

BD: Onboard 6 new clinics. Pilot patch SKU.

United Arab Emirates

ACTIVE

Premium longevity hub. Kingdom Holdings interest + regional partner.

BUSINESS DEVELOPMENT

BD: Expand Pens + Peptual to 3 new clinics. UAE Pen launch.

Mexico / Latin America

PENDING REG.

Distribution partner in place. Awaiting Cofepris approval.

BUSINESS DEVELOPMENT

BD: Cofepris filing in progress. Anchor for LatAm rollout.

Leadership.



Management, board, and scientific advisory with expertise across healthcare, biotech, fintech, and public markets.



Dr. Pradeep Albert MD
Chief Executive Officer

Dr. Pradeep Albert is the Chief Executive Officer of Vesalius Longevity Labs, leading the company's strategy, regulatory alignment, and clinical integrity dedicated to peptide, regenerative, and longevity science.

A physician-executive with over 20 years of experience, Dr. Albert brings deep expertise across regenerative medicine, advanced diagnostics, and highly regulated healthcare environments. His background spans clinical practice, healthcare entrepreneurship, and global medical innovation, with a proven ability to translate emerging science into scalable, compliant, and commercially viable platforms. Dr. Albert's leadership anchors Vesalius' institutional-grade standards, ensuring scientific rigor, regulatory discipline, and long-term credibility as the company scales globally.



Dr. Michael Roizen MD
Chief Scientific Advisor

Dr. Michael Roizen is a pioneering physician-scientist who served as the first Chief Wellness Officer at Cleveland Clinic—the first such position at a major U.S. healthcare institution. Board-certified in both Internal Medicine and Anesthesiology, he trained at Harvard and the NIH alongside Nobel laureate Julius Axelrod. Dr. Roizen has chaired top-ranked departments at the University of Chicago and served as Dean of the School of Medicine at SUNY Upstate. A prolific researcher with 185+ peer-reviewed publications and 13 U.S. patents, he co-invented an FDA-approved drug and has chaired FDA advisory committees. As co-author of four #1 New York Times bestsellers—including the landmark YOU: The Owner's Manual series with Dr. Mehmet Oz—he has shaped how millions understand health optimization and longevity. Dr. Roizen brings unparalleled credibility in translating cutting-edge science into real-world wellness outcomes.

The team.



Management, board, and scientific advisory with expertise across healthcare, biotech, fintech, and public markets.



Timmi Stump
Chief Operating/Commercial Officer



Chris Cooper
Chief Financial Officer



Vatsal Patel
Chief Technology Officer



Jenna Larson
Senior Director, Sales



Natalie Cavelero
Director, Operations



Julia Becker
Vice President, Capital Markets

Strategic advisors.



All advisors are investors and strategically aligned with the Vesalius vision across health, performance, and wellness verticals.

INFLUENTIAL LEADERS IN THE SPACE ~50M SOCIAL REACH



Gary Brecka

The Ultimate Human,
Human Biologist



Brigham Buhler

Health Care Entrepreneur



Chris Bumstead

Titan of Fitness &
Business Acumen



George Kittle

NFL Superstar &
Entrepreneur



Cedric Gervais

Cultural Architect of Wellness

Board of Directors.

Deep expertise in global brand building



James McRoberts, Chairman



James McRoberts, Executive Chairman MuseCell Innovations PTD LTD, is a veteran entrepreneur and early member of Optimal Payments, part of the circa 1995 group of companies such as Confinity, Novo Payments and Authorize.net working in the digital payments ecosystem vastly similar to the challenges faced today by regenerative medicine. With more than two decades leading and scaling ventures across fintech and biotech, he brings deep operational expertise and a track record of building high-growth regulated businesses.

David Adelman, Board Director



David Adelman is a prominent entrepreneur and investor with 30+ years of experience building and backing category-defining companies.

He is CEO of Campus Apartments, co-founder of FS Investments, and founder of Darco Capital, where he invests across real estate, technology, consumer brands, and life sciences. Adelman is also a minority owner of the Philadelphia 76ers and New Jersey Devils.

Kevin Mayer, Board Director



Kevin Mayer is a seasoned global media and technology executive best known for his nearly three-decade career at The Walt Disney Company. He served as Chairman of Direct-to-Consumer & International, where he led the global launch of Disney+, Hulu, and ESPN+, and previously as Chief Strategy Officer, overseeing the landmark acquisitions of Pixar, Marvel, Lucasfilm, and 21st Century Fox. Following Disney, Mr. Mayer briefly served as CEO of TikTok in 2020 and is currently Co-Founder and Co-CEO of Candle Media, a next-generation media company.

Kevin Serre PhD, Board Director



Kevin Serre, Ph.D., is the President of Dezawa High Performance (DHP), a wholly owned subsidiary of MuseCell Innovations PTD LTD. As a of DHP, Kevin is responsible for the application of MCI technology with their professional sport and elite Military partners.

Kevin formerly worked as the Human Performance lead for the Canadian Department of Defense (CANSOFCOM).

Brent Saunders, Board Director



Brent Saunders is a globally recognized healthcare executive and board leader with more than 25 years of experience building and scaling category-defining companies. He has served as CEO or Chairman of major pharmaceutical and healthcare organizations including Allergan, Bausch + Lomb, Forest Laboratories, and Vesper Healthcare, leading over \$150 billion in transformative M&A transactions, including the \$63 billion sale of Allergan to AbbVie. Known for driving blockbuster product growth, global commercial expansion, and complex integrations to the board.



World Class Scientific Advisory Board.



Dr. Rowan Paul, MD

A pioneer, thought leader, and expert in the field of regenerative orthopedics since 2009. As an Assistant Professor at Dartmouth's Geisel School of Medicine, Dr. Paul has a deep passion for teaching. He is published in the field of Regenerative Medicine and has contributed to multiple textbooks and key scientific papers to the industry.



Dr. Dominik Duscher, MD, PhD

A specialist in longevity medicine, Dr. Duscher is the Chief Medical Officer of MuseCell Innovations PTE LTD. He is a bestselling author, consultant and entrepreneur. After studying at the Medical University of Vienna, University College London and Harvard Medical School, he completed a postdoctoral fellowship in Stem Cell Biology and Regenerative Medicine at Stanford University.



Dr. Vijay Vad, MD

Dr. Vijay Vad is double board certified in physical medicine and rehabilitation (physiatry) and sports medicine. In addition to treating patients at the prestigious Hospital for Special Surgery out of NYC, Dr. Vad has previously served as the physician for the professional men's tennis circuit (Association of Tennis Professionals, ATP) as well as the physician for the Westchester Classic of the PGA Tour, and MSG Tennis Showdown.



Dr. Matt Cook, MD DR., FAARM, ABAARM

Dr. Cook is a leading regenerative medicine specialist in regenerative and longevity medicine, recognized for advancing next-generation cellular, peptide, and neuro-immune therapies. Through Bio Reset® Medical and Vesalius Longevity Labs, he develops personalized, data-driven protocols that restore function, optimize performance, and extend healthspan.



Dr. Melissa Grill-Petersen DR., DC, MS, BCHH

Dr. Melissa Petersen, founder of the Human Longevity Institute, is a visionary leader in precision longevity, epigenetics, and human potential, dedicated to optimizing health and well-being.



Dr. Steven Murphy, MD, DABIM, DABOM

Dr. Murphy is trained in Internal Medicine, Regenerative Therapies, Obesity Medicine and Hyperbaric Medicine with a specialization in Genetics from Yale. Dr. Murphy incorporates therapies like PRP, peptides, and stem cells to repair and rejuvenate tissues at a cellular level.



Dr. Jonathann Kuo, MD

Dr. Jonathann Kuo is a double board-certified physician, founder of Hudson Health and Extension Health, specializing in regenerative medicine, pain management, and anti-aging therapies.



Dr. Jeffrey Wieggers MD, ABA-PM

Dr. Wieggers is a board-certified anesthesiologist and interventional pain specialist advancing regenerative therapies. Trained at UMKC and Cedars-Sinai, he brings strong clinical expertise to innovative pain and recovery solutions.



Capitalization table.



VLAB

TICKER (CSE)

\$70M

MARKET CAP

GO PUBLIC PROCESS

- 'LOI' Letter of Intent

Definitive Agreement

Listing Statement

Trading Date
- 


IMMINENT

Sept 2026

RESULTING ISSUER CAP TABLE

Shares	100,828,965
Options	5,850,000
RSUs	2,000,000
Warrants	10,434,750
Total diluted I.O	119,113,715
Cash	US\$6.5 million
Debt	N/A



Thank You

Jules Becker

VP, Capital Markets

jbecker@vesaliuslabs.com

www.vesaliuslabs.com